Relationship between circulating anti-thyroglobulin antibodies (TgAb) and tumor metabolism in patients with differentiated thyroid cancer (DTC): prognostic implications

Verburg FA, Luster M, Cupini C, Chiovato L, Duntas L, Elisei R, Feldt-Rasmussen U, Rimmele H, Seregni E, Smit JW, Theimer C, Giovanella L (2013) Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement. Thyroid 23:1211–1225

Chiovato L, Latrofa F, Braverman LE, Pacini F, Capezzone M, Masserini L, Grasso L, Pinchera A (2003) Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 139:346–351

Pacini F, Mariotti S, Formica N, Elisei R, Anelli S, Capotorti E, Pinchera A (1988) Thyroid autoantibodies in thyroid cancer: incidence and relationship with tumour outcome. Acta Endocrinol. (Copenh) 119:373–380

Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM (2009) American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214

Spencer CA (2011) Clinical review: clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC). J Clin Endocrinol Metab 96:3615–3627

Pacini F, Brianzoni E, Durante C, Elisei R, Ferdeghini M, Fugazzola L, Mariotti S, Pellegriti G (2016) Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology. J Endocrinol Invest 39:341–347

Rubello D, Casara D, Girelli ME, Piccolo M, Busnardo B (1992) Clinical meaning of circulating antithyroglobulin antibodies in differentiated thyroid cancer: a prospective study. J Nucl Med 33:1478–1480

Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA, Fatemi S, LoPresti JS, Nicoloff JT (1998) Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 83:1121–1127

Chung JK, Park YJ, Kim TY, So Y, Kim SK, Park DJ, Lee DS, Lee MC, Cho BY (2002) Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol 57:215–221

Kim WG, Yoon JH, Kim WB, Kim TY, Kim EY, Kim JM, Ryu JS, Gong G, Hong SJ, Shong YK (2008) Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 93:4683–4689

Durante C, Tognini S, Montesano T, Orlandi F, Torlontano M, Puxeddu E, Attard M, Costante G, Tumino S, Meringolo D, Bruno R, Trulli F, Toteda M, Redler A, Ronga G, Filetti S, Monzani F, PTC Study Group (2014) Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies. Thyroid 24:1139–1145

Kumar A, Shah DH, Shrihari U, Dandekar SR, Vijayan U, Sharma SM (1994) Significance of antithyroglobulin autoantibodies in differentiated thyroid carcinoma. Thyroid 4:199–202

Görges R, Maniecki M, Jentzen W, Sheu SN, Mann K, Bockisch A, Janssen OE (2005) Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur J Endocrinol 153:49–55

Leboulleux S, El Bez I, Borget I, Elleuch M, Déandreis D, Al Ghuzlan A, Chougnet C, Bidault F, Mirghani H, Lumbroso J, Hartl D, Baudin E, Schlumberger M (2012) Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels. Thyroid 22:832–838

Morbelli S, Bagnasco M (2014) Differentiated thyroid cancer incidentally detected by18F-FDG PET/CT: patient’s future in a hot-spot? Eur J Nucl Med Mol Imaging 41:1479–1481

Nascimento C, Borget I, Al Ghuzlan A, Deandreis D, Hartl D, Lumbroso J, Berdelou A, Lepoutre-Lussey C, Mirghani H, Baudin E, Schlumberger M, Leboulleux S (2015) Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer. Thyroid 25:437–444

Deandreis D, Al Ghuzlan A, Leboulleux S, Lacroix L, Garsim JP, Talbot M, Lumbroso J, Baudin E, Caillou B, Bidart JM, Schlumberger M (2011) Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome? Endocr Relat Cancer 18:159–169

Rivera M, Ghossein RA, Schoder H, Gomez D, Larson SM, Tuttle RM (2008) Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer 113:48–56

Batista FA, Ward LS, Marcello MA, Martins MB, Peres KC, Torricelli C, Bufalo NE, Soares FA, da Silva MJ, Assumpção LV (2016) Gene expression of thyroid-specific transcription factors may help diagnose thyroid lesions but are not determinants of tumor progression. J Endocrinol Invest 39:423–429

Seo JH, Lee SW, Ahn BC, Lee J (2010) Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG PET/CT. Clinic Endocr (Oxford) 72:558–563

Görges R, Maniecki M, Jentzen W, Sheu SN, Mann K, Bockisch A, Janssen OE (2005) Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur J Endocrinol 153:49–55

Rubio IG, Silva MN, Knobel M, Romão R, Possato R, Gebrin EM, Buchpiguel C, Medeiros-Neto G (2007) Peripheral blood levels of thyroglobulin mRNA and serum thyroglobulin concentrations after radioiodine ablation of multinodular goiter with or without pre-treatment with recombinant human thyrotropin. J Endocrinol Invest 30:535–540

Hsieh CJ, Wang PW (2014) Sequential changes of serum antithyroglobulin antibody levels are a good predictor of disease activity in thyroglobulin-negative patients with papillary thyroid carcinoma. Thyroid 24:488–493

Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A, Krause BJ (2015) FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328–354

Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W (2006) European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787–803

Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, Tuttle RM, Drucker W, Larson SM (2006) Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-d-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91:498–505

Piccardo A, Puntoni M, Bertagna F, Treglia G, Foppiani L, Arecco F, Giubbini R, Naseri M, Cistaro A, Cabria M, Bardesono F, Ceriani L, Orlandi F, Giovanella L (2014) 18F-FDG uptake as a prognostic variable in primary differentiated thyroid cancer incidentally detected by PET/CT: a multicentre study. Eur J Nucl Med Mol Imaging 41:1482–1491

Feine U, Lietzenmayer R, Hanke JP, Held J, Wöhrle H, Müller-Schauenburg W (1996) Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 37:1468–1472

Latrofa F, Ricci D, Montanelli L, Rocchi R, Piaggi P, Sisti E, Grasso L, Basolo F, Ugolini C, Pinchera A, Vitti P (2012) Thyroglobulin autoantibodies in patients with papillary thyroid carcinoma: comparison of different assays and evaluation of causes of discrepancies. J Clin Endocrinol Metab 97:3974–3982

Giovanella L, Toffalori E, Tozzoli R, Caputo M, Ceriani L, Verburg FA (2012) Multiplexed immunoassay of thyroglobulin autoantibodies in patients with differentiated thyroid carcinoma. Head Neck 34:1369–1371

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L (2016) 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid 26:1–133